Physician profile
Patrick J Riddle
NPI 1811992993
$4,093.56
in general payments reported to CMS, 2019-2025
28 companies · $697 in 2025
The $697 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $518 · 2020: $408 · 2021: $311 · 2022: $359 · 2023: $935 · 2024: $866 · 2025: $697.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,497.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,496.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $538.72 | 2019-2024 | Rocklatan, Clareon, Rhopressa |
| Bausch & Lomb Americas INC. | $493.19 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Abbvie INC. | $338.72 | 2022-2025 | |
| Oyster Point Pharma, INC. | $312.09 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $265.06 | 2019-2021 | |
| Amgen INC. | $250.31 | 2024-2025 | Tepezza |
| Aerie Pharmaceuticals, INC. | $240.35 | 2019-2021 | |
| Astellas Pharma US INC | $210.75 | 2023-2025 | Izervay |
| Horizon Therapeutics Plc | $183.40 | 2022-2023 | Tepezza |
| Kala Pharmaceuticals, INC. | $181.47 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $163.64 | 2019-2023 | |
| Mallinckrodt Hospital Products INC. | $157.35 | 2024-2025 | Acthar |
| Dompe US, INC. | $127.05 | 2024-2025 | Oxervate |
| Allergan, INC. | $97.35 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $94.16 | 2019-2025 | Cequa |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apellis Pharmaceuticals, INC. | $91.41 | 2024-2025 | Syfovre |
| Iridex Corporation | $69.88 | 2019 | |
| Rayner Intraocular Lenses Limited | $39.64 | 2022-2023 | Omidria, Rayone Emv, Rayone Aspheric |
| Johnson & Johnson Vision Care, INC. | $38.56 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $29.84 | 2025 | Xdemvy |
| Ani Pharmaceuticals, INC. | $25.27 | 2025 | Purified Cortrophin Gel |
| Glaukos Corporation | $24.91 | 2024 | Idose |
| Regeneron Healthcare Solutions, INC. | $24.72 | 2025 | Eylea Hd |
| Coopervision INC. | $23.70 | 2019 | |
| Vyera Pharmaceuticals, LLC | $22.06 | 2022 | |
| Sight Sciences, INC. | $20.41 | 2020 | |
| Omeros Corporation | $15.06 | 2019 | |
| Shire North American Group INC | $14.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Riddle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.